GB201504840D0 - Chimeric antigen receptor - Google Patents

Chimeric antigen receptor

Info

Publication number
GB201504840D0
GB201504840D0 GBGB1504840.8A GB201504840A GB201504840D0 GB 201504840 D0 GB201504840 D0 GB 201504840D0 GB 201504840 A GB201504840 A GB 201504840A GB 201504840 D0 GB201504840 D0 GB 201504840D0
Authority
GB
United Kingdom
Prior art keywords
antigen receptor
chimeric antigen
chimeric
receptor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1504840.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1504840.8A priority Critical patent/GB201504840D0/en
Publication of GB201504840D0 publication Critical patent/GB201504840D0/en
Priority to PT167124247T priority patent/PT3274366T/pt
Priority to AU2016238583A priority patent/AU2016238583B2/en
Priority to PCT/GB2016/050795 priority patent/WO2016151315A1/en
Priority to ES16712424T priority patent/ES2773527T3/es
Priority to NZ735267A priority patent/NZ735267B2/en
Priority to SG11201706940QA priority patent/SG11201706940QA/en
Priority to CA2978852A priority patent/CA2978852C/en
Priority to US15/560,558 priority patent/US11058722B2/en
Priority to CN201680017370.3A priority patent/CN107406518B/zh
Priority to PL16712424T priority patent/PL3274366T3/pl
Priority to DK16712424.7T priority patent/DK3274366T3/da
Priority to BR112017018252-1A priority patent/BR112017018252A2/pt
Priority to KR1020177030391A priority patent/KR102174280B1/ko
Priority to JP2017549766A priority patent/JP6675417B2/ja
Priority to RU2017132978A priority patent/RU2752880C2/ru
Priority to MX2017010552A priority patent/MX371384B/es
Priority to EP16712424.7A priority patent/EP3274366B8/en
Priority to HUE16712424A priority patent/HUE047929T2/hu
Priority to ZA2017/05682A priority patent/ZA201705682B/en
Priority to IL254254A priority patent/IL254254B/en
Priority to CL2017002413A priority patent/CL2017002413A1/es
Priority to JP2020001971A priority patent/JP2020048588A/ja
Priority to JP2022201192A priority patent/JP2023021396A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB1504840.8A 2015-03-23 2015-03-23 Chimeric antigen receptor Ceased GB201504840D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB1504840.8A GB201504840D0 (en) 2015-03-23 2015-03-23 Chimeric antigen receptor
HUE16712424A HUE047929T2 (hu) 2015-03-23 2016-03-22 Kiméra antigén receptor
PL16712424T PL3274366T3 (pl) 2015-03-23 2016-03-22 Chimeryczny receptor antygenowy
BR112017018252-1A BR112017018252A2 (pt) 2015-03-23 2016-03-22 receptores de antígenos quiméricos
PCT/GB2016/050795 WO2016151315A1 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor
ES16712424T ES2773527T3 (es) 2015-03-23 2016-03-22 Receptor quimérico para antígeno
NZ735267A NZ735267B2 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor
SG11201706940QA SG11201706940QA (en) 2015-03-23 2016-03-22 Chimeric antigen receptor
CA2978852A CA2978852C (en) 2015-03-23 2016-03-22 Chimeric antigen receptor
US15/560,558 US11058722B2 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain
CN201680017370.3A CN107406518B (zh) 2015-03-23 2016-03-22 嵌合抗原受体
PT167124247T PT3274366T (pt) 2015-03-23 2016-03-22 Recetor de antigénio quimérico
DK16712424.7T DK3274366T3 (da) 2015-03-23 2016-03-22 Kimær antigenreceptor
AU2016238583A AU2016238583B2 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor
KR1020177030391A KR102174280B1 (ko) 2015-03-23 2016-03-22 키메라 항원 수용체
JP2017549766A JP6675417B2 (ja) 2015-03-23 2016-03-22 キメラ抗原受容体
RU2017132978A RU2752880C2 (ru) 2015-03-23 2016-03-22 Химерный антигенный рецептор
MX2017010552A MX371384B (es) 2015-03-23 2016-03-22 Receptor antigenico quimerico.
EP16712424.7A EP3274366B8 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor
ZA2017/05682A ZA201705682B (en) 2015-03-23 2017-08-21 Chimeric antigen receptor
IL254254A IL254254B (en) 2015-03-23 2017-08-31 chimeric antigen receptor
CL2017002413A CL2017002413A1 (es) 2015-03-23 2017-09-25 Receptor antigénico quimérico
JP2020001971A JP2020048588A (ja) 2015-03-23 2020-01-09 キメラ抗原受容体
JP2022201192A JP2023021396A (ja) 2015-03-23 2022-12-16 キメラ抗原受容体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504840.8A GB201504840D0 (en) 2015-03-23 2015-03-23 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
GB201504840D0 true GB201504840D0 (en) 2015-05-06

Family

ID=53052211

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1504840.8A Ceased GB201504840D0 (en) 2015-03-23 2015-03-23 Chimeric antigen receptor

Country Status (21)

Country Link
US (1) US11058722B2 (enExample)
EP (1) EP3274366B8 (enExample)
JP (3) JP6675417B2 (enExample)
KR (1) KR102174280B1 (enExample)
CN (1) CN107406518B (enExample)
AU (1) AU2016238583B2 (enExample)
BR (1) BR112017018252A2 (enExample)
CA (1) CA2978852C (enExample)
CL (1) CL2017002413A1 (enExample)
DK (1) DK3274366T3 (enExample)
ES (1) ES2773527T3 (enExample)
GB (1) GB201504840D0 (enExample)
HU (1) HUE047929T2 (enExample)
IL (1) IL254254B (enExample)
MX (1) MX371384B (enExample)
PL (1) PL3274366T3 (enExample)
PT (1) PT3274366T (enExample)
RU (1) RU2752880C2 (enExample)
SG (1) SG11201706940QA (enExample)
WO (1) WO2016151315A1 (enExample)
ZA (1) ZA201705682B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
JP2020511992A (ja) * 2017-03-29 2020-04-23 サニーブルック リサーチ インスティテュート 遺伝子組換えｔ細胞調節分子およびその使用方法
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3621981A2 (en) 2017-05-12 2020-03-18 CRISPR Therapeutics AG Materials and methods for engineering cells and uses thereof in immuno-oncology
JP2020530993A (ja) * 2017-08-02 2020-11-05 オートラス リミテッド キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
JP2021500930A (ja) * 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｐボディ−多価標的結合物質
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
CN112105420A (zh) 2018-05-11 2020-12-18 克里斯珀医疗股份公司 用于治疗癌症的方法和组合物
CN112119096B (zh) 2018-05-15 2024-04-30 奥托路斯有限公司 嵌合抗原受体
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CN112930186A (zh) * 2018-08-16 2021-06-08 纪念斯隆-凯特琳癌症中心 基于亮氨酸拉链的组合物和使用方法
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
MX2021003636A (es) 2018-09-27 2021-07-21 Autolus Ltd Receptor antigenico quimerico.
KR20210072797A (ko) * 2018-10-05 2021-06-17 세인트 안나 킨더크렙스포르슝 키메라 항원 수용체(car) 그룹
CA3109747A1 (en) * 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
WO2020172643A2 (en) * 2019-02-21 2020-08-27 Luk John M Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
WO2020222176A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202017649D0 (en) 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
WO2022182891A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US20250288672A1 (en) * 2021-03-24 2025-09-18 Raymond Liu Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) * 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2024019961A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cd2 recruiting chimeric antigen receptors and fusion proteins
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2010102518A1 (zh) 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
KR101156085B1 (ko) * 2010-01-29 2012-06-20 국립암센터 ４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도
US10745467B2 (en) * 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
JP6053688B2 (ja) * 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
CN111676196A (zh) * 2012-05-25 2020-09-18 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
DK2893004T3 (en) 2012-09-04 2019-02-04 Cellectis MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF
KR102332790B1 (ko) * 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
PT3083671T (pt) * 2013-12-20 2020-12-24 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e recetores destas
CN107074957B (zh) 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor

Also Published As

Publication number Publication date
ES2773527T3 (es) 2020-07-13
MX371384B (es) 2020-01-28
IL254254A0 (en) 2017-10-31
AU2016238583B2 (en) 2020-08-13
CN107406518A (zh) 2017-11-28
WO2016151315A1 (en) 2016-09-29
EP3274366B1 (en) 2019-12-11
KR20180009738A (ko) 2018-01-29
JP6675417B2 (ja) 2020-04-01
RU2752880C2 (ru) 2021-08-11
CA2978852A1 (en) 2016-09-29
US20180050065A1 (en) 2018-02-22
RU2017132978A3 (enExample) 2019-06-24
AU2016238583A1 (en) 2017-09-28
EP3274366B8 (en) 2020-02-12
EP3274366A1 (en) 2018-01-31
CL2017002413A1 (es) 2018-03-16
CN107406518B (zh) 2022-02-01
US11058722B2 (en) 2021-07-13
SG11201706940QA (en) 2017-09-28
NZ735267A (en) 2021-04-30
HUE047929T2 (hu) 2020-05-28
PL3274366T3 (pl) 2020-06-15
JP2023021396A (ja) 2023-02-10
BR112017018252A2 (pt) 2018-04-10
MX2017010552A (es) 2018-03-14
JP2018510639A (ja) 2018-04-19
JP2020048588A (ja) 2020-04-02
DK3274366T3 (da) 2020-02-10
KR102174280B1 (ko) 2020-11-04
ZA201705682B (en) 2018-12-19
CA2978852C (en) 2021-10-19
RU2017132978A (ru) 2019-04-08
PT3274366T (pt) 2020-01-30
IL254254B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
IL254254A0 (en) chimeric antigen receptor
GB201503742D0 (en) Chimeric antigen receptor
SG11201606790XA (en) Chimeric antigen receptor
IL250536A0 (en) Chimeric antigen receptors
IL251030A0 (en) Chimeric antigen receptors
IL258527A (en) Chimeric Antigen Receptors Against Sorting Group 30
PL3294764T3 (pl) Kompozycje chimerycznego receptora antygenowego
IL252783A0 (en) bcma chimeric antigen receptors
GB201617290D0 (en) Novel chimeric antigen receptors
GB201607968D0 (en) Chimeric antigen receptor
ZA201700730B (en) Bcma chimeric antigen receptors
GB201610512D0 (en) Chimeric antigen receptor
EP3256496A4 (en) Chimeric antigen receptors
ZA201906321B (en) Chimeric antigen receptor
GB201709508D0 (en) Chimeric antigen receptor
GB201519900D0 (en) Chimeric antigen receptor
GB201721421D0 (en) Chimeric antigen receptor
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201612844D0 (en) Chimeric antigen receptor
GB201612533D0 (en) Chimeric antigen receptor
GB201604387D0 (en) Chimeric antigen receptor
GB201409761D0 (en) Chimeric antigen receptor
GB201403481D0 (en) Chimeric antigen receptor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)